Boston Scientific (BSX) Capital Expenditures (2009 - 2026)

Boston Scientific has disclosed Capital Expenditures across 18 years of filings, most recently posting $177.0 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $177.0 million, down 5.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $866.0 million (up 8.52% YoY), and the FY2025 annual result was $876.0 million, up 10.89% from the prior year.
• Capital Expenditures came in at $177.0 million for Q1 2026 at Boston Scientific, down from $351.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $351.0 million in Q4 2025 to a low of $105.0 million in Q2 2022.
• The 5-year median for Capital Expenditures is $179.0 million (2024), against an average of $184.8 million.
• Peak annual rise in Capital Expenditures reached 61.33% in 2022, while the deepest fall reached 20.3% in 2022.
• Boston Scientific's Capital Expenditures stood at $212.0 million in 2022, then gained by 25.94% to $267.0 million in 2023, then advanced by 3.75% to $277.0 million in 2024, then climbed by 26.71% to $351.0 million in 2025, then slumped by 49.57% to $177.0 million in 2026.
• The last three Capital Expenditures figures came in at $177.0 million (Q1 2026), $351.0 million (Q4 2025), and $181.0 million (Q3 2025), per Business Quant data.